~~BRIEF~~ SUMMARY

[005a] In one aspect, the present disclosure provides the use of a pharmaceutical composition in the manufacture of a medicament for treating birch allergy in a subject, wherein the pharmaceutical composition comprises: (a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or (b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or (c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

[006] In one ~~aspect~~example, methods of treating birch allergy in a subject are provided. In some embodiments, the method comprises administering to the subject one or more pharmaceutical compositions comprising:

(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or

(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the

amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or

(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

[006a] In one aspect, the present disclosure provides the use of a pharmaceutical composition in the manufacture of a medicament for reducing one or more symptoms of an allergic reaction to a Fagales allergen in a subject, wherein the pharmaceutical composition comprises: (a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or (b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or (c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

[007] In another ~~aspect~~example, methods of reducing one or more symptoms of an allergic reaction to a Fagales allergen in a subject are provided. In some ~~embodiment~~examples, the method comprises administering to the subject one or more pharmaceutical compositions comprising:

(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, an LCDR1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or

(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an

HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or

(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

[008] In some ~~embodiment~~examples, the Fagales allergen is Bet v 1. In some ~~embodiment~~examples, the subject is sensitized to Bet v 1 and to at least one other Fagales allergen. In some ~~embodiment~~examples, the at least one other Fagales allergen is alder, hazel, oak, hornbeam, hop-hornbeam, beech, chestnut, hazelnut, or apple.

[009] In another ~~aspect~~example, methods of treating a subject having seasonal or perennial allergy associated with birch and cross-reacting pollens are provided. In some ~~embodiment~~examples, the subject has moderate-to-severe seasonal allergy or moderate-to-severe perennial allergy. In some ~~embodiment~~examples, the method comprises administering to the subject one or more pharmaceutical compositions comprising:

(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, an LCDR1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or

(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or

(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino

acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

[010] For the methods disclosed herein, in some ~~embodiment~~examples the pharmaceutical composition comprises the first anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the second anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the third anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the first anti-Bet v 1 antibody and the second anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the first anti-Bet v 1 antibody and the third anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the second anti-Bet v 1 antibody and the third anti-Bet v 1 antibody. In some ~~embodiment~~examples, the pharmaceutical composition comprises the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody.

[011] In some ~~embodiment~~examples, the anti-Bet v 1 antibodies are provided in a single pharmaceutical composition. In some ~~embodiment~~examples, the anti-Bet v 1 antibodies are provided in more than one pharmaceutical composition, e.g., each anti-Bet v 1 antibody in a separate pharmaceutical composition.

[012] In some ~~embodiment~~examples, the pharmaceutical composition(s) comprises the anti-Bet v 1 antibody or antibodies (e.g., each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody) at an independently selected dose of about 5 mg to about 500 mg. In some ~~embodiment~~examples, the pharmaceutical composition(s) comprises the anti-Bet v 1 antibody or antibodies (e.g., each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody) at an independently selected dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg. In some ~~embodiment~~examples, the pharmaceutical composition(s) comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 50 mg. In some ~~embodiment~~examples, the pharmaceutical composition(s) comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 150 mg. In some ~~embodiment~~examples, the pharmaceutical composition(s) comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 300 mg.

[013] In some ~~embodiment~~examples, the anti-Bet v 1 antibody or antibodies, or the pharmaceutical composition comprising the anti-Bet v 1 antibody or antibodies, is administered subcutaneously. In some ~~embodiment~~examples, the anti-Bet v 1 antibody or antibodies, or the pharmaceutical composition comprising the anti-Bet v 1 antibody or antibodies, is administered intravenously.

[014] In some ~~embodiment~~examples, a single dose of the anti-Bet v 1 antibody or antibodies, or the pharmaceutical composition comprising the anti-Bet v 1 antibody or antibodies, is administered. In some ~~embodiment~~examples, the anti-Bet v 1 antibody or antibodies, or the pharmaceutical composition comprising the anti-Bet v 1 antibody or antibodies, is administered once before the start of pollen season.

[015] In some ~~embodiment~~examples, the first anti-Bet v 1 antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:5. In some ~~embodiment~~examples, the first anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

[016] In some ~~embodiment~~examples, the second anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:11 and an LCVR comprising the amino acid sequence of SEQ ID NO:15. In some ~~embodiment~~examples, the second anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

[017] In some ~~embodiment~~examples, the third anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:21 and an LCVR comprising the amino acid sequence of SEQ ID NO:25. In some ~~embodiment~~examples, the third anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30.

[018] In some ~~embodiment~~examples, treatment with the pharmaceutical composition:

reduces a subject's Total Nasal Symptom Score (TNSS);

reduces a subject's Total Ocular Symptom Score (TOSS);

reduces a subject's Total Symptom Score (TSS);

reduces a subject's Daily Medication Score (DMS);

reduces a subject's Combined Symptom and Medication Score (CSMS);

reduces a subject's birch skin prick test (SPT) mean wheal diameter; and/or

increases a subject's number of "well days" in which rescue medication is not utilized and the subject's TSS is ≤2 of 18.

[019] In some ~~embodiment~~examples, the TNSS, TOSS, TSS, DMS, CSMS, SPT mean wheal diameter, and/or number of well days is measured over at least 28, 57, 85, or 113 days. In some ~~embodiment~~examples, the TNSS, TOSS, TSS, DMS, CSMS, SPT mean wheal diameter, and/or number of well days is measured over the duration of birch pollen season.

[020] In some ~~embodiment~~examples, treatment with the pharmaceutical composition reduces allergic rhinitis symptoms in the subject. In some ~~embodiment~~examples, treatment with the pharmaceutical composition: reduces a subject's Total Nasal Symptom Score (TNSS) AUC

(0-1 hr) after nasal allergen challenge (NAC) (e.g., by at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more), relative to a baseline TNSS AUC (0-1 hr) value after NAC for the subject prior to the onset of treatment; and/or reduces a subject's peak TNSS after NAC (e.g., by at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more), relative to a baseline peak TNSS value after NAC for the subject prior to the onset of treatment.

[021] In some ~~embodiment~~example, administration of a single dose of the pharmaceutical composition: reduces a subject's TNSS AUC (0-1 hr) after NAC by at least about 20% for at least two months after the pharmaceutical composition is administered; and/or reduces a subject's peak TNSS after NAC by at least about 25% for at least two months after the pharmaceutical composition is administered.

[022] In some ~~embodiment~~example, treatment with the pharmaceutical composition reduces allergic conjunctivitis symptoms in the subject. In some ~~embodiment~~example, treatment with the pharmaceutical composition: reduces a subject's Total Ocular Symptom Score (TOSS) (e.g., by at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more), relative to a baseline TOSS value for the subject prior to the onset of treatment; and/or reduces a subject's TOSS AUC (0-1 hr) after NAC (e.g., by at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more), relative to a baseline TOSS AUC (0-1 hr) value after NAC for the subject prior to the onset of treatment.

[023] In some ~~embodiment~~example, treatment with the pharmaceutical composition reduces a subject's combined symptom and medication score (CSMS) during birch pollen season (e.g., by at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more), relative to a baseline CSMS for the subject prior to the onset of treatment or a control CSMS.

[024] In some ~~embodiment~~example, treatment with the pharmaceutical composition improves peak nasal inspiratory flow (PNIF) in the subject (e.g., by at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more), relative to a baseline PNIF value for the subject prior to the onset of treatment.

[025] In some ~~embodiment~~example, treatment with the pharmaceutical composition reduces birch sensitization in the subject (e.g., by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) as measured by a skin prick test (SPT) with a birch allergen extract. In some ~~embodiment~~example, administration of a single dose of the pharmaceutical composition reduces birch sensitization in the subject by at least about 60% or more for at least two months (e.g., at least three months, at least four months, at least five months, or at least six months) after the pharmaceutical composition is administered.

[026] In some ~~embodiment~~example, the subject to be treated has a baseline serum allergen-specific IgE level ≥ 0.35 kUa/L for the allergen (e.g., birch tree pollen, Bet v 1 allergen, or Fagales allergen). In some ~~embodiment~~example, the subject to be treated has a baseline positive SPT with an allergen (e.g., birch allergen extract or Fagales allergen).

[027] In another ~~aspect~~example, a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof for use in a method of treating birch allergy in a subject is provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having birch allergy).

[028] In another ~~aspect~~example, the use of a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof in the manufacture of a medicament for use in a method of treating birch allergy in a subject is provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having birch allergy).

[029] In another ~~aspect~~example, a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof for use in a method of reducing one or more symptoms of an allergic reaction to a Fagales allergen in a subject is provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having one or more symptoms of an allergic reaction to a Fagales allergen).

[030] In another ~~aspect~~example, the use of a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof in the manufacture of a medicament for use in a method of reducing one or more symptoms of an allergic reaction to a Fagales allergen in a subject is provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having one or more symptoms of an allergic reaction to a Fagales allergen).

[031] In another ~~aspect~~example, a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof for use in a method of treating a subject having seasonal or perennial allergy associated with birch and cross-reacting pollens are provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having seasonal or perennial allergy associated with birch and cross-reacting pollens are provided).

[032] In another ~~aspect~~example, the use of a cocktail comprising two or more anti-Bet v 1 antibodies or antigen-binding fragments thereof in the manufacture of a medicament for use in a method of treating a subject having seasonal or perennial allergy associated with birch and cross-reacting pollens are provided. In some ~~embodiment~~examples, the method comprises administering the cocktail as disclosed herein to a subject in need thereof (e.g., a subject having seasonal or perennial allergy associated with birch and cross-reacting pollens are provided).

[033] Other ~~embodiment~~examples will be apparent from a review of the ensuing detailed description.

What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for ~~A method of~~ treating birch allergy in a subject, ~~the method comprising administering to the subject a~~wherein the pharmaceutical composition ~~comprising~~comprises:

(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or

(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or

(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

2. The ~~method~~ use of claim 1, wherein the pharmaceutical composition comprises the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody.

3. The use~~method~~ of claim 2, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of ~~about~~ 5 mg to ~~about~~ 500 mg.

4. The use~~method~~ of claim 3, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 50 mg.

5. The use~~method~~ of claim 3, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 150 mg.

6. The use~~method~~ of claim 3, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 300 mg.

7. The use~~method~~ of any one of claims 1 to 6, wherein the pharmaceutical composition is to be administered subcutaneously.

8. The use~~method~~ of any one of claims 1 to 6, wherein the pharmaceutical composition is to be administered intravenously.

9. The ~~method~~ use of any one of claims 1 to 8, wherein a single dose of the pharmaceutical composition is to be administered prior to the start of birch pollen season.

10. The use~~method~~ of any one of claims 1 to 9, wherein the first anti-Bet v 1 antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:5.

11. The ~~method~~ use of claim 10, wherein the first anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

12. The ~~method~~ use of any one of claims 1 to 9, wherein the second anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:11 and an LCVR comprising the amino acid sequence of SEQ ID NO:15.

13. The ~~method~~ use of claim 12, wherein the second anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

14. The ~~method~~ use of any one of claims 1 to 9, wherein the third anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:21 and an LCVR comprising the amino acid sequence of SEQ ID NO:25.

15. The ~~method~~ use of claim 14, wherein the third anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30.

16. The ~~method~~ use of any one of claims 1 to 15, wherein ~~treatment with~~ the pharmaceutical composition:

reduces a subject's Total Nasal Symptom Score (TNSS);

reduces a subject's Total Ocular Symptom Score (TOSS);

reduces a subject's Total Symptom Score (TSS);

reduces a subject's Daily Medication Score (DMS);

reduces a subject's Combined Symptom and Medication Score (CSMS);

reduces a subject's birch skin prick test (SPT) mean wheal diameter; and/or

increases a subject's number of well days in which rescue medication is not utilized and the subject's TSS is ≤2 of 18.

17. The ~~method~~ use of claim 16, wherein ~~treatment with~~ the pharmaceutical composition reduces a subject's TNSS, TOSS, TSS, DMS, and/or CSMS for the duration of birch pollen season.

18. The ~~method~~ use of any one of claims 1 to 17, wherein ~~treatment with~~ the pharmaceutical composition reduces allergic rhinitis symptoms in the subject.

19. The ~~method~~ use of claim 18, wherein ~~treatment with~~ the pharmaceutical composition:

reduces a subject's Total Nasal Symptom Score (TNSS) AUC (0-1 hr) after nasal allergen challenge (NAC) by at least about 20%, relative to a baseline TNSS AUC (0-1 hr) value after NAC for the subject prior to the onset of treatment; and/or

reduces a subject's peak TNSS after NAC by at least about 25%, relative to a baseline peak TNSS value after NAC for the subject prior to the onset of treatment.

20. The ~~method~~ use of claim 19, wherein administration of a single dose of the pharmaceutical composition:

reduces a subject's TNSS AUC (0-1 hr) after NAC by at least about 20% for at least two months after the pharmaceutical composition is to be administered; and/or

reduces a subject's peak TNSS after NAC by at least about 25% for at least two months after the pharmaceutical composition is to be administered.

21. The ~~method~~ use of any one of claims 1 to 20, wherein ~~treatment with~~ the pharmaceutical composition reduces allergic conjunctivitis symptoms in the subject.

22. The ~~method~~ use of claim 21, wherein ~~treatment with~~ the pharmaceutical composition reduces a subject's TOSS AUC (0-1 hr) after NAC, relative to a baseline TOSS AUC (0-1 hr) value after NAC for the subject prior to the onset of treatment.

23. The ~~method~~ use of any one of claims 1 to 22, wherein ~~treatment with~~ the pharmaceutical composition improves peak nasal inspiratory flow (PNIF) in the subject by at least about 30%, relative to a baseline PNIF value for the subject prior to the onset of treatment.

24. The ~~method~~ use of any one of claims 1 to 23, wherein ~~treatment with~~ the pharmaceutical composition reduces birch sensitization in the subject by at least about 50% as measured by a skin prick test (SPT) with a birch allergen extract.

25. The ~~method~~ use of claim 24, wherein administration of a single dose of the pharmaceutical composition reduces birch sensitization in the subject by at least about 60% for at least two months after the pharmaceutical composition is to be administered.

26. The ~~method~~ use of any one of claims 1 to 25, wherein the subject to be treated has a baseline serum allergen-specific IgE level ≥ 0.35 kUa/L for birch tree pollen and/or Bet v 1 allergen.

27. The ~~method~~ use of any one of claims 1 to 26, wherein the subject to be treated has a baseline positive SPT with a birch allergen extract.

28. Use of a pharmaceutical composition in the manufacture of a medicament for ~~A method of~~ reducing one or more symptoms of an allergic reaction to a Fagales allergen in a subject, ~~the method comprising administering to the subject a pharmaceutical composition comprising~~wherein the pharmaceutical composition comprises:

(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or

(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or

(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28.

29. The ~~method~~ use of claim 28, wherein the Fagales allergen is Bet v 1.

30. The ~~method~~ use of claim 28 or 29, wherein the subject is sensitized to Bet v 1 and to at least one other Fagales allergen.

31. The ~~method~~ use of any one of claims 28 to 30, wherein the pharmaceutical composition comprises the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody.

32. The ~~method~~ use of claim 31, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of ~~about~~ 5 mg to ~~about~~ 500 mg.

33. The ~~method~~ use of claim 32, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 50 mg.

34. The ~~method~~ use of claim 32, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 150 mg.

35. The ~~method~~ use of claim 32, wherein the pharmaceutical composition comprises each of the first anti-Bet v 1 antibody, the second anti-Bet v 1 antibody, and the third anti-Bet v 1 antibody at a dose of about 300 mg.

36. The ~~method~~ use of any one of claims 28 to 35, wherein the pharmaceutical composition is to be administered subcutaneously.

37. The ~~method~~ use of any one of claims 28 to 35, wherein the pharmaceutical composition is to be administered intravenously.

38. The ~~method~~ use of any one of claims 28 to 37, wherein the first anti-Bet v 1 antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:5.

39. The ~~method~~ use of claim 38, wherein the first anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

40. The ~~method~~ use of any one of claims 28 to 37, wherein the second anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:11 and an LCVR comprising the amino acid sequence of SEQ ID NO:15.

41. The ~~method~~ use of claim 40, wherein the second anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

42. The ~~method~~ use of any one of claims 28 to 37, wherein the third anti-Bet v 1 antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO:21 and an LCVR comprising the amino acid sequence of SEQ ID NO:25.

43. The ~~method~~ use of claim 42, wherein the third anti-Bet v 1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29 and a light chain comprising the amino acid sequence of SEQ ID NO:30.

44. The ~~method~~ use of any one of claims 28 to 43, wherein ~~treatment with~~ the pharmaceutical composition reduces allergic rhinitis symptoms in the subject.

45. The use~~method~~ of any one of claims 28 to 44, wherein ~~treatment with~~ the pharmaceutical composition reduces allergic conjunctivitis symptoms in the subject.

46. The use~~method~~ of any one of claims 28 to 45, wherein ~~treatment with~~ the pharmaceutical composition reduces sensitization to the Fagales allergen in the subject.

47. The use~~method~~ of any one of claims 28 to 46, wherein the subject to be treated has a baseline serum allergen-specific IgE level ≥ 0.35 kUa/L for the Fagales allergen.

48. The use~~method~~ of any one of claims 28 to 47, wherein the subject to be treated has a baseline positive SPT to the Fagales allergen.